

Study ID	Year	Age	Country	Region	Study design	Study population	Study period	Sample size	Loss to follow-up	Sex	Age	Height	Blood pressure										Systolic blood pressure	Diastolic blood pressure	Pulse pressure	Mean arterial pressure	Cardiovascular morbidity	Cardiovascular mortality															
													SBP	DBP	PP	MAP	SBP	DBP	PP	MAP	SBP	DBP							PP	MAP													
Study 1	2018	65-74	China	East Asia	Cross-sectional	General population	2010-2012	100,000	5%	Male	65-74	170-180	SBP	135	85	50	93	135	85	50	93	135	85	50	93	135	85	50	93	135	85	50	93	135	85	50	93						
													DBP	85	50	93	85	50	93	85	50	93	85	50	93	85	50	93	85	50	93	85	50	93	85	50	93	85	50	93	85	50	93
													PP	50	93	85	50	93	85	50	93	85	50	93	85	50	93	85	50	93	85	50	93	85	50	93	85	50	93	85	50	93	85
Study 2	2019	75-84	India	South Asia	Cross-sectional	General population	2015-2017	150,000	10%	Male	75-84	160-170	SBP	145	95	50	95	145	95	50	95	145	95	50	95	145	95	50	95	145	95	50	95	145	95	50	95						
													DBP	95	50	95	95	50	95	95	50	95	95	50	95	95	50	95	95	50	95	95	50	95	95	50	95	95	50	95	95	50	95
													PP	50	95	95	50	95	95	50	95	95	50	95	95	50	95	95	50	95	95	50	95	95	50	95	95	50	95	95	50	95	95
Study 3	2020	85-94	Brazil	South America	Cross-sectional	General population	2018-2020	80,000	15%	Male	85-94	170-180	SBP	155	105	50	100	155	105	50	100	155	105	50	100	155	105	50	100	155	105	50	100	155	105	50	100						
													DBP	105	50	100	105	50	100	105	50	100	105	50	100	105	50	100	105	50	100	105	50	100	105	50	100	105	50	100	105	50	100
													PP	50	100	100	50	100	100	50	100	100	50	100	100	50	100	100	50	100	100	50	100	100	50	100	100	50	100	100	50	100	100

Study ID	Year	Author	Country	Study Design	Population	Intervention	Comparator	Outcome	Effect Size	95% CI	Quality	Notes	
10.1136/bmjgh-2021-007735	2021	Liu et al.	China	Cohort	General population	Vitamin D	Placebo	Mortality	HR	0.85	0.72-1.00	High	Study of Vitamin D supplementation in a general population.
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
10.1136/bmjgh-2021-007735	2021	Liu et al.	China	Cohort	General population	Vitamin D	Placebo	Mortality	HR	0.85	0.72-1.00	High	Study of Vitamin D supplementation in a general population.
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
10.1136/bmjgh-2021-007735	2021	Liu et al.	China	Cohort	General population	Vitamin D	Placebo	Mortality	HR	0.85	0.72-1.00	High	Study of Vitamin D supplementation in a general population.
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
10.1136/bmjgh-2021-007735	2021	Liu et al.	China	Cohort	General population	Vitamin D	Placebo	Mortality	HR	0.85	0.72-1.00	High	Study of Vitamin D supplementation in a general population.
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	
										0.85	0.72-1.00	High	

Study ID	Year	Country	Study Design	Intervention	Comparator	Outcome	Effect Size	95% CI	P-value	Quality of Evidence	Bias	Confounding	Missing Data	Reporting Bias	Other	Relative Risk (95% CI)		Number Needed to Treat (95% CI)		N	N
																RR	CI	NNT	CI		
Study 1	2018	Kenya	Randomized Controlled Trial	Vaccination	Control	Incidence of malaria	0.15	0.10-0.20	0.0001	High	No	No	No	No	No	0.15	0.10-0.20	6.7	5.0-9.0	1000	1000
																0.15	0.10-0.20	6.7	5.0-9.0		
Study 2	2019	Kenya	Randomized Controlled Trial	Vaccination	Control	Incidence of malaria	0.12	0.08-0.16	0.0001	High	No	No	No	No	No	0.12	0.08-0.16	8.3	6.3-11.0	1000	1000
																0.12	0.08-0.16	8.3	6.3-11.0		
Study 3	2020	Kenya	Randomized Controlled Trial	Vaccination	Control	Incidence of malaria	0.18	0.13-0.23	0.0001	High	No	No	No	No	No	0.18	0.13-0.23	5.6	4.2-7.5	1000	1000
																0.18	0.13-0.23	5.6	4.2-7.5		
Study 4	2021	Kenya	Randomized Controlled Trial	Vaccination	Control	Incidence of malaria	0.14	0.10-0.18	0.0001	High	No	No	No	No	No	0.14	0.10-0.18	7.1	5.4-9.4	1000	1000
																0.14	0.10-0.18	7.1	5.4-9.4		
Study 5	2022	Kenya	Randomized Controlled Trial	Vaccination	Control	Incidence of malaria	0.16	0.12-0.20	0.0001	High	No	No	No	No	No	0.16	0.12-0.20	6.3	4.7-8.4	1000	1000
																0.16	0.12-0.20	6.3	4.7-8.4		

Study ID	Year	Country	Study Design	Population	Intervention	Comparator	Outcome	Effect Size	95% CI	P-value	Quality of Evidence	Sample Size		Events		Relative Risk	95% CI	P-value	Quality of Evidence
												Intervention	Comparator	Intervention	Comparator				
Study 1	2021	India	Cohort	Healthcare workers	Vaccination	No vaccination	Incidence of COVID-19	0.001	[0.000, 0.002]	0.001	High	1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
												1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
Study 2	2021	India	Cohort	Healthcare workers	Vaccination	No vaccination	Incidence of COVID-19	0.001	[0.000, 0.002]	0.001	High	1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
												1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
Study 3	2021	India	Cohort	Healthcare workers	Vaccination	No vaccination	Incidence of COVID-19	0.001	[0.000, 0.002]	0.001	High	1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
												1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
Study 4	2021	India	Cohort	Healthcare workers	Vaccination	No vaccination	Incidence of COVID-19	0.001	[0.000, 0.002]	0.001	High	1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
												1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
Study 5	2021	India	Cohort	Healthcare workers	Vaccination	No vaccination	Incidence of COVID-19	0.001	[0.000, 0.002]	0.001	High	1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
												1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
Study 6	2021	India	Cohort	Healthcare workers	Vaccination	No vaccination	Incidence of COVID-19	0.001	[0.000, 0.002]	0.001	High	1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
												1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
Study 7	2021	India	Cohort	Healthcare workers	Vaccination	No vaccination	Incidence of COVID-19	0.001	[0.000, 0.002]	0.001	High	1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
												1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
Study 8	2021	India	Cohort	Healthcare workers	Vaccination	No vaccination	Incidence of COVID-19	0.001	[0.000, 0.002]	0.001	High	1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
												1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
Study 9	2021	India	Cohort	Healthcare workers	Vaccination	No vaccination	Incidence of COVID-19	0.001	[0.000, 0.002]	0.001	High	1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
												1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
Study 10	2021	India	Cohort	Healthcare workers	Vaccination	No vaccination	Incidence of COVID-19	0.001	[0.000, 0.002]	0.001	High	1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High
												1000	1000	10	10	1.0	[0.8, 1.2]	0.95	High

Study ID	Year	Country	Study Design	Population	Intervention	Comparator	Outcome	Effect Size	95% CI	P-value	Quality of Evidence	Heterogeneity		I-squared		Tau-squared	P-value						
												I-squared	P-value	I-squared	P-value								
Study 1	2018	India	Randomized controlled trial	Adults aged 18-65 years	Vitamin D supplement	Placebo	Incidence of fractures	Relative risk	0.85	[0.75, 0.95]	0.001	High	0.0	0.99	0.00	0.99	0.00	0.99					
																			Age	18-24	0.85	[0.75, 0.95]	0.001
																			Age	25-34	0.85	[0.75, 0.95]	0.001
																			Age	35-44	0.85	[0.75, 0.95]	0.001
																			Age	45-54	0.85	[0.75, 0.95]	0.001
																			Age	55-64	0.85	[0.75, 0.95]	0.001
																			Age	65-74	0.85	[0.75, 0.95]	0.001
																			Age	75-84	0.85	[0.75, 0.95]	0.001
																			Age	85-94	0.85	[0.75, 0.95]	0.001
																			Age	95-104	0.85	[0.75, 0.95]	0.001
Study 2	2019	India	Randomized controlled trial	Adults aged 18-65 years	Vitamin D supplement	Placebo	Incidence of fractures	Relative risk	0.85	[0.75, 0.95]	0.001	High	0.0	0.99	0.00	0.99	0.00	0.99					
																			Age	18-24	0.85	[0.75, 0.95]	0.001
																			Age	25-34	0.85	[0.75, 0.95]	0.001
																			Age	35-44	0.85	[0.75, 0.95]	0.001
																			Age	45-54	0.85	[0.75, 0.95]	0.001
																			Age	55-64	0.85	[0.75, 0.95]	0.001
																			Age	65-74	0.85	[0.75, 0.95]	0.001
																			Age	75-84	0.85	[0.75, 0.95]	0.001
																			Age	85-94	0.85	[0.75, 0.95]	0.001
																			Age	95-104	0.85	[0.75, 0.95]	0.001
Study 3	2020	India	Randomized controlled trial	Adults aged 18-65 years	Vitamin D supplement	Placebo	Incidence of fractures	Relative risk	0.85	[0.75, 0.95]	0.001	High	0.0	0.99	0.00	0.99	0.00	0.99					
																			Age	18-24	0.85	[0.75, 0.95]	0.001
																			Age	25-34	0.85	[0.75, 0.95]	0.001
																			Age	35-44	0.85	[0.75, 0.95]	0.001
																			Age	45-54	0.85	[0.75, 0.95]	0.001
																			Age	55-64	0.85	[0.75, 0.95]	0.001
																			Age	65-74	0.85	[0.75, 0.95]	0.001
																			Age	75-84	0.85	[0.75, 0.95]	0.001
																			Age	85-94	0.85	[0.75, 0.95]	0.001
																			Age	95-104	0.85	[0.75, 0.95]	0.001
Study 4	2021	India	Randomized controlled trial	Adults aged 18-65 years	Vitamin D supplement	Placebo	Incidence of fractures	Relative risk	0.85	[0.75, 0.95]	0.001	High	0.0	0.99	0.00	0.99	0.00	0.99					
																			Age	18-24	0.85	[0.75, 0.95]	0.001
																			Age	25-34	0.85	[0.75, 0.95]	0.001
																			Age	35-44	0.85	[0.75, 0.95]	0.001
																			Age	45-54	0.85	[0.75, 0.95]	0.001
																			Age	55-64	0.85	[0.75, 0.95]	0.001
																			Age	65-74	0.85	[0.75, 0.95]	0.001
																			Age	75-84	0.85	[0.75, 0.95]	0.001
																			Age	85-94	0.85	[0.75, 0.95]	0.001
																			Age	95-104	0.85	[0.75, 0.95]	0.001